Jennifer Soung, MD

Use of Combination Therapy in Atopic Dermatitis

Video content above is prompted by the following:

How often are your patients using combination therapy to manage their disease?

Videos

Panelists discuss the frequency of combination therapy use in managing atopic dermatitis, highlighting its role in enhancing treatment efficacy and addressing multifactorial aspects of the disease in their patient population.

Switching or Staying Within the Treatment Class

Can you talk about when we should consider switching to another biologic or when to go with a different mechanism of action?

Panelists discuss when to consider switching to another biologic or exploring a different mechanism of action in atopic dermatitis treatment, focusing on factors like inadequate response, adverse effects, or the need for more targeted therapy to optimize patient outcomes.

Less Frequent Administration of Lebrikizumab for Atopic Dermatitis

Can you discuss maintenance of treatment efficacy in the lebrikizumab clinical trial?

Panelists discuss the maintenance of treatment efficacy in the lebrikizumab clinical trial, highlighting data on sustained improvement in atopic dermatitis symptoms over time and the long-term effectiveness of the treatment.

Efficacy Data With IL-13 Targeting Agents in Atopic Dermatitis

Please give an overview of latest efficacy and safety data with IL-13–targeting therapies in AD, including recently presented data.

Panelists provide an overview of the latest efficacy and safety data for IL-13–targeting therapies in atopic dermatitis (AD), including recently presented data on dupilumab, lebrikizumab, and tralokinumab, focusing on their effectiveness in symptom reduction and safety profiles across patient populations.

Jennifer Soung, MD

Articles